- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-0100
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Combined treatment of somatostatin analogues with pegvisomant in acromegaly ; volume:52 ; number:2 ; day:10 ; month:12 ; year:2015 ; pages:206-213 ; date:5.2016
Endocrine ; 52, Heft 2 (10.12.2015), 206-213, 5.2016
- Urheber
-
Franck, S. E.
- Beteiligte Personen und Organisationen
-
Muhammad, A.
Lely, A. J. van der
Neggers, S. J. C. M. M.
SpringerLink (Online service)
- DOI
-
10.1007/s12020-015-0810-8
- URN
-
urn:nbn:de:1111-201604093607
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Franck, S. E.
- Muhammad, A.
- Lely, A. J. van der
- Neggers, S. J. C. M. M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Somatostatin analogues labeled with copper radioisotopes: current status
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Somatostatin analogues labeled with copper radioisotopes: current status
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Somatostatin analogues labeled with copper radioisotopes: current status
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors